CEACAM5 and gastric cancer: The prediction signature of the pathomics-driven ensemble model continued to be an independent predictor for progression-free survival in patients with GC who underwent immunotherapy when multivariable Cox regression was adjusted for clinicopathological variables, such as the sex, age, carcinoembryonic antigen, carbohydrate antigen 19-9, therapy regime, line of therapy, differentiation, location, and PD-L1 expression in all patients (p < 0.001, hazard ratio (HR) 0.35 (95% CI 0.24 to 0.50)).